*Supplementary Material*

# Clinical Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: a Real-World Analysis in Italy

Luca Degli Esposti,[1*] Melania Dovizio,[1] Valentina Perrone,[1] Chiara Veronesi,[1] Margherita Andretta,[2] Marcello Bacca,[3] Antonietta Barbieri,[4] Fausto Bartolini,[5] Arturo Cavaliere,[6] Alessandro Chinellato,[7] Andrea Ciaccia,[8] Mariarosaria Cillo,[9] Rita Citraro,[10] Alberto Costantini,[11] Stefania Dell'Orco,[12] Fulvio Ferrante,[13] Simona Gentile,[14] Stefano Grego,[15] Daniela Mancini,[3] Rossella Moscogiuri,[16] Elena Mosele,[17] Romina Pagliaro,[18] Cataldo Procacci,[19] Davide Re,[20] Fiorenzo Santoleri,[10] Loredana Ubertazzo,[21] Adriano Vercellone,[22] Antonio Ramirez de Arellano,[23] Giuseppe Gigliotti,[24] Luca Quartuccio[25]

[1] CliCon Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy

[2] Azienda ULSS 8 Berica, Vicenza, Italy

[3] ASL Brindisi, Brindisi, Italy

[4] ASL Vercelli, Vercelli, Italy

[5] USL Umbria 2, Terni, Italy

[6] ASL Viterbo, Viterbo, Italy

[7] Azienda ULSS 3 Serenissima, Mestre (VE), Italy

[8] ASL Foggia, Foggia, Italy

[9] ASL Salerno, Salerno, Italy

[10] Dipartimento di Scienze della Salute, Università Magna Grecia di Catanzaro, Unità Operativa Di Farmacologia Clinica e Farmacovigilanza, Azienda Ospedaliero-Universitaria "Mater Domini", Catanzaro, Italy

[11] ASL Pescara, Pescara, Italy

[12] ASL RM 6, Albano Laziale RM, Italy

[13] ASL Frosinone, Frosinone, Italy

[14] Direzione Generale per la Salute Regione Molise, Campobasso, Italy

[15] ASL3 Genovese, Genova, Italy

[16] ASL Taranto, Taranto, Italy

[17] Azienda ULSS 7 Pedemontana, Bassano del Grappa (VI), Italy

[18] Azienda Sanitaria Locale Roma 5, Tivoli, Italy

[19] ASL BAT, Andria (BT), Italy

[20] ASL Teramo, Teramo, Italy

[21] ASL Roma 4, Civitavecchia (RM), Italy

[22] ASL Napoli 3 Sud, Napoli, Italy

[23] Vifor Pharma Group, Glattbrugg, Switzerland

[24] UOC Nefrologia e Dialisi, Ospedale di Eboli, Salerno, Italy

[25] Dipartimento di Medicina (DAME), Clinica di Reumatologia, Università degli Studi di Udine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy

*Correspondence: Luca Degli Esposti, CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Via Murri, 9 - 40137 Bologna, Italy; phone + 39 (0)544 38393; fax: + 39 (0)544 212699; e-mail: luca.degliesposti@clicon.it

**Table S1.** The 10 most frequently prescribed drugs in the two cohorts during the characterization period.

| ATC | Prescription | GPA patients (N=713) | MPA patients (N=146) |
|---|---|---|---|
| J01 | Antibacterials for systemic use | 554 (77.7%) | 107 (73.3%) |
| H02 | Corticosteroids for systemic use | 551 (77.3%) | 108 (74.0%) |
| A02 | Drugs for acid related disorders | 531 (74.5%) | 123 (84.2%) |
| R03 | Drugs for obstructive airway diseases | 381 (53.4%) | 43 (29.5%) |
| C09 | Agents acting on the renin-angiotensin system | 271 (38.0%) | 76 (52.1%) |
| A11 | Vitamins | 269 (37.7%) | 79 (54.1%) |
| M01 | Anti-inflammatory and antirheumatic products | 218 (30.6%) | 42 (28.8%) |
| B01 | Antithrombotic agents | 217 (30.4%) | 61 (41.8%) |
| L04 | Immunosuppressive agents | 207 (29.0%) | 39 (26.7%) |
| B03 | Antianemic preparations | 183 (25.7%) | 50 (34.2%) |

**Table S2.** The 10 most frequent causes of hospitalization in the two cohorts during the characterization period.

| **Description** | **GPA patients (N=713)** | **MPA patients (N=146)** |
|---|---|---|
| Musculoskeletal system and connective tissue | 105 (14.7%) | 21 (14.4%) |
| Respiratory system | 88 (12.3%) | 8 (5.5%) |
| Kidney and urinary tract | 50 (7.0%) | 24 (16.4%) |
| Circulatory system | 42 (5.9%) | 6 (4.1%) |
| Ear, nose, mouth and throat | 27 (3.8%) | -* |
| Infectious and parasitic diseases/disorders | 19 (2.7%) | 4 (2.7%) |
| Skin, subcutaneous tissue and breast | 17 (2.4%) | -* |
| Nervous system | 17 (2.4%) | 8 (5.5%) |
| Digestive system | 12 (1.7%) | 4 (2.7%) |
| Blood and blood forming organs/immunological disorders | 11 (1.5%) | -* |

** not present in the 10-most frequently prescribed drugs list*

**Table S3.** The 10 most frequently prescribed drugs in the two cohorts at one-year follow-up.

| ATC | Prescription | GPA patients (N=713) | MPA patients (N=146) |
|---|---|---|---|
| H02 | Corticosteroids for systemic use | 566 (79.4%) | 115 (78.8%) |
| A02 | Drugs for acid related disorders | 536 (75.2%) | 125 (85.6%) |
| J01 | Antibacterials for systemic use | 499 (70.0%) | 101 (69.2%) |
| A11 | Vitamins | 357 (50.1%) | 83 (56.8%) |
| R03 | Drugs for obstructive airway diseases | 319 (44.7%) | 37 (25.3%) |
| L04 | Immunosuppressive agents | 272 (38.1%) | 58 (39.7%) |
| C09 | Agents acting on the renin-angiotensin system | 242 (33.9%) | 68 (46.6%) |
| B01 | Antithrombotic agents | 232 (32.5%) | 60 (41.1%) |
| B03 | Antianemic preparations | 212 (29.7%) | 51 (34.9%) |
| C03 | Diuretics | 195 (27.3%) | 56 (38.4%) |

**Table S4**. GLM model to evaluate predictors of mean annual cost among AAV patients. Significant p values are highlighted in bold.

| | **β Coefficient €** | **[95% confidence interval]** | | **P value** |
|---|---|---|---|---|
| Diagnosis of MPA (ref. GPA) | +963.06 | -13.65 | 1939.76 | 0.053 |
| Hospitalization as inclusion criteria (ref. exemption code) | +12,583.75 | 9843.63 | 15,323.88 | **<0.001** |
| Use of glucocorticoids | +1486.87 | 680.05 | 2293.70 | **<0.001** |
| Age | +28.25 | 7.85 | 48.65 | **<0.01** |
| Male gender | -312.80 | -947.29 | 321.70 | 0.334 |
| Charlson comorbidity index | +1142.45 | 546.64 | 1738.26 | **<0.001** |
| Constant | -13,376.83 | -16,328.34 | -10,425.32 | <0.001 |